ライフサイエンスコーパス: antineoplastic

1 y referred to as cisplatin, is a widely used antineoplastic.

2 rotein contributes to clinical resistance to antineoplastics.

3 oprotein or vitamin C retention modulated by antineoplastics.

4 to additional purine analogues, such as the antineoplastic, 2-chloro-2'-deoxyadenosine (cladribine)

5 DNA damage by FTIs may be critical for their antineoplastic action as a class.

6 -independent properties are important to the antineoplastic action of this class of drugs.

7 Antineoplastic actions could result from effects on over

8 rug metformin has been shown to exert strong antineoplastic actions in numerous tumor types, includin

9 nsferase (FTase) inhibitors (FTI) have broad antineoplastic actions targeting both cancer cells and m

10 THZ1 demonstrated pronounced antineoplastic activities both in vitro and in vivo An i

11 Thus, the antineoplastic activities of metformin in pancreatic can

12 Their antineoplastic activities were assessed against the cult

13 n present in grapes, nuts, and red wine, has antineoplastic activities.

14 ine, a steroid alkaloid that shows promising antineoplastic activities.

15 CL single-chain fragment variable displaying antineoplastic activity against established solid tumors

16 ma, we discovered that ailanthone had potent antineoplastic activity against HCC.

17 Cyclopentenone prostaglandins exhibit unique antineoplastic activity and are potent growth inhibitors

18 active immunomodulatory drug that has direct antineoplastic activity and indirect effects mediated th

19 Molecular mechanisms of trastuzumab antineoplastic activity and potential mechanisms contrib

20 According to these results, the antineoplastic activity and safety of TPP(+)C10 warrant

21 LY293111 has antineoplastic activity in a variety of preclinical mode

22 atment of type II diabetes, clearly exhibits antineoplastic activity in experimental models and has b

23 the p53 tumor suppressor are central to its antineoplastic activity in vivo.

24 diation therapy (RT) was believed to mediate antineoplastic activity mostly (if not only) as a conseq

25 been shown to play an important role in the antineoplastic activity of 5-fluorouracil (5-FU) and in

26 ibitor (LY294002) was able to potentiate the antineoplastic activity of both doxorubicin and paclitax

27 rapamycin provided the first evidence of the antineoplastic activity of mTOR inhibitors in humans, be

28 de a mechanism for the previously postulated antineoplastic activity of quinolones, and suggest that

29 This study tests the tolerance and antineoplastic activity of sequential infusions of parti

30 enin signaling significantly potentiates the antineoplastic activity of the Plk1 inhibitor BI2536 in

31 o BRAF or MEK1/2 inhibitors and enhanced the antineoplastic activity of these inhibitors.

32 ortezomib or carfilzomib would have stronger antineoplastic activity than combinations currently used

33 cal trials that use this mechanism for their antineoplastic activity, making synthetic lethality one

34 l product halichondrin B, has recently shown antineoplastic activity, with relatively low incidence a

35 this compound or related biguanides may have antineoplastic activity.

36 s a novel, selective inhibitor of Mps-1 with antineoplastic activity.

37 its effect on bone metabolism and not on its antineoplastic activity.

38 nograft models, miR-150 upregulation induced antineoplastic activity.

39 The antineoplastic agent benzyl isothiocyanate (BITC) acts b

40 clude the aminoglycoside antibiotics and the antineoplastic agent cisplatin.

41 n vitro and in vivo tumor sensitivity to the antineoplastic agent doxorubicin.

42 our data, bortezomib represents a promising antineoplastic agent for the treatment of ATC.

43 , a PP2A inhibitor which has been used as an antineoplastic agent in clinical trials, is also able to

44 th RXR-selective ligand may thus be a useful antineoplastic agent in differentiation induction therap

45 IFN-alpha is an antineoplastic agent in the treatment of several solid a

46 idoreductase 1 (NQO1) on the activity of the antineoplastic agent mitomycin C (MC) under aerobic and

47 ne compound previously used clinically as an antineoplastic agent potentiates the presynaptic functio

48 Bortezomib (PS-341) is a novel antineoplastic agent that is well tolerated at doses not

49 Cisplatin is a commonly used antineoplastic agent that produces ototoxicity that is m

50 Paclitaxel (Taxol) is a frontline antineoplastic agent used to treat a variety of solid tu

51 Deoxynyboquinone (DNQ) is a potent antineoplastic agent with an unknown mechanism of action

52 Doxorubicin is a highly effective antineoplastic agent, but it can produce the serious sid

53 Imatinib, an antineoplastic agent, demonstrated antiinflammatory and

54 inical use of doxorubicin, widely used as an antineoplastic agent, is markedly hampered by severe car

55 the side effects of cisplatin, a widely used antineoplastic agent, major efforts have been made to de

56 ated the effect of bryostatin-1 (Bryo-1), an antineoplastic agent, on dendritic cell (DC) maturation,

57 rent clinical assessment of clioquinol as an antineoplastic agent.

58 n attractive candidate for development as an antineoplastic agent.

59 hibitor developed specifically for use as an antineoplastic agent.

60 door for clinical trials evaluating it as an antineoplastic agent.

61 linical information on gallium nitrate as an antineoplastic agent.

62 e II diabetes that has gained interest as an antineoplastic agent.

63 )F-FLT) in assessing its effectiveness as an antineoplastic agent.

64 apeutic tool for hypersensitivity to several antineoplastic agents (oxaliplatin, carboplatin, paclita

65 In this study, we examined whether antineoplastic agents 5-fluorouracil (5-FU) and dacarbaz

66 tide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the his

67 city that are reported to be associated with antineoplastic agents and discuss their putative mechani

68 ic investigation of PPARdelta antagonists as antineoplastic agents and implicate altered PPARdelta-cy

69 , for a 1-year period, suffered reactions to antineoplastic agents and were referred to the Desensiti

70 in C given before mechanistically dissimilar antineoplastic agents antagonizes therapeutic efficacy i

71 Taxane antineoplastic agents are extensively taken up into hepa

72 -870,893 alone and in combination with other antineoplastic agents are warranted.

73 o asparaginyl residues and that DNA-damaging antineoplastic agents as well as other stimuli can incre

74 f advanced-stage NSCLC and were treated with antineoplastic agents between 2000 and 2011 (N = 22,163)

75 ion can affect the sensitivity of cancers to antineoplastic agents by altering expression of genes cr

76 e induction of a senescent-like phenotype by antineoplastic agents can contribute therapeutic efficac

77 ce or its displacement from the chromatin by antineoplastic agents caused an increase in the levels o

78 Currently, FTIs are being explored as antineoplastic agents for the treatment of several malig

79 orubicin (DOXO) is one of the most effective antineoplastic agents in clinical practice.

80 d consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are recei

81 timal dose for use in combination with other antineoplastic agents in pediatric patients.

82 Approximately 44% of patients received antineoplastic agents in the last 30 days of life throug

83 Desensitization to antineoplastic agents is becoming a standard of care.

84 tial for increased exposure of the tumour to antineoplastic agents leading to improved cytotoxicity.

85 Antineoplastic agents loaded on 50-100-microm microspher

86 storically, it has been well recognized that antineoplastic agents may have adverse effects on multip

87 as osteosarcoma, for preclinical testing of antineoplastic agents offers significant advantages over

88 antiemetic regimens that are appropriate for antineoplastic agents or radiotherapy being administered

89 mens for adults who receive high-emetic-risk antineoplastic agents or who experience breakthrough nau

90 Targeted antineoplastic agents show great promise in the treatmen

91 The common use of antineoplastic agents such as mitomycin C, doxorubicin,

92 All antineoplastic agents tested caused mitochondrial membra

93 nd colony formation after treatment with all antineoplastic agents tested.

94 In contrast to most other antineoplastic agents that generate reactive oxygen spec

95 at can enhance the efficacy of biguanides as antineoplastic agents that target cancer cell energy met

96 rease in apoptosis in cells treated with the antineoplastic agents that was not due to up-regulation

97 apy, 51 candidate genes from the pathways of antineoplastic agents were resequenced to identify commo

98 is likely that interest in CDK inhibitors as antineoplastic agents will continue for the foreseeable

99 b, alone or in combination with the standard antineoplastic agents, 5-fluoruracil or irinotecan.

100 n of cellular apoptotic responses to various antineoplastic agents, a laser-based technology, Optopho

101 kers has revealed many potential targets for antineoplastic agents, and a particularly important aber

102 argeting of these immunosuppressive cells by antineoplastic agents, and consider current challenges a

103 pathy is a dose-limiting side effect of many antineoplastic agents, but the mechanisms underlying the

104 ate the response of an individual's tumor to antineoplastic agents, but these tumor fragments are cul

105 activity of multiple widely used classes of antineoplastic agents, human cancer cell lines were trea

106 The performance and safety of current antineoplastic agents, particularly water-insoluble drug

107 n deazapurines as antibiotic, antiviral, and antineoplastic agents, the biosynthetic route toward dea

108 ew the development of successful preclinical antineoplastic agents, their associated limitations, and

109 iatric patients who receive high-emetic-risk antineoplastic agents.

110 tients who are treated with high emetic risk antineoplastic agents.

111 for designing biocompatible target specific antineoplastic agents.

112 described possible activity of quinolones as antineoplastic agents.

113 lation to cytotoxic chemotherapy or targeted antineoplastic agents.

114 resistance to paclitaxel and possibly other antineoplastic agents.

115 entify complex III as a potential target for antineoplastic agents.

116 e proposal that these ligands may be used as antineoplastic agents.

117 reast cancer cells to cytoskeletal targeting antineoplastic agents.

118 logic utility as angiogenesis inhibitors and antineoplastic agents.

119 by current or previous treatment with other antineoplastic agents.

120 hione conjugates and several natural product antineoplastic agents.

121 ed for cancer cell apoptosis induced by many antineoplastic agents.

122 metabolism and may be a suitable target for antineoplastic agents.

123 a group, are unresponsive to treatment with antineoplastic agents.

124 l scaffold to improve the design of specific antineoplastic agents.

125 olecules targeting translation initiation as antineoplastic agents.

126 multiple oncoproteins may lead to effective antineoplastic agents.

127 ifaceted approach for the development of new antineoplastic agents.

128 to improve performance and safety of current antineoplastic agents.

129 mbining different classes of agents that are antineoplastic and also inhibit bone destruction and inc

130 Activation of PPAR isoforms elicits both antineoplastic and anti-inflammatory effects in several

131 is a natural product known to possess potent antineoplastic and antiangiogenic properties.

132 Lenalidomide, an immunomodulatory drug with antineoplastic and antiproliferative effects, showed act

133 ported data based on more than 100 DPTs with antineoplastic and biological agents (paclitaxel, oxalip

134 e regarding drug provocation test (DPT) with antineoplastic and biological agents is scarce.

135 poptotic factor and is a novel target of the antineoplastic and cardiomyopathic drug doxorubicin (Dox

136 nd modulator of protein kinase C that exerts antineoplastic and immunomodulatory activities both in v

137 ic prodrugs with no equivalent among current antineoplastics and whose selective action toward breast

138 is a cytokine with potent immunoregulatory, antineoplastic, and antiviral properties.

139 folate metabolism and an important target of antineoplastic, antimicrobial, and antiinflammatory drug

140 ion of many psychotropic, immunosuppressant, antineoplastic, antimicrobial, and cardiovascular drugs,

141 be developed further as a novel therapeutic antineoplastic approach.

142 cid conjugated to cytotoxics, a new class of antineoplastics, are transported into cells via FR-media

143 also sustain copy number loss in GBM through antineoplastic assay and identified A2BP1 (ataxin 2 bind

144 he utility of our method using zebrafish for antineoplastic candidate drug identification and suggest

145 CE-355621 is an efficacious novel antineoplastic chemotherapeutic agent that inhibits (18)

146 Antineoplastic chemotherapeutic agents may indirectly ac

147 e tested the effects of different classes of antineoplastic chemotherapeutic agents used in low noncy

148 Age is not a contraindication of antineoplastic chemotherapy as long as it is based on ph

149 itors to mTOR inhibitors, as alternatives to antineoplastic chemotherapy, along with the use of antih

150 history of gastric bleeding, breast cancer, antineoplastic chemotherapy, and prednisone use presente

151 orbidity and mortality in patients receiving antineoplastic chemotherapy.

152 arsenic trioxide (As(2)O(3)), a very potent antineoplastic compound for the treatment of acute promy

153 amoxicillin, cephalexin and cefadroxil, the antineoplastics delta-aminolevulinic acid (delta-ALA) an

154 gest a potential role for S-nitrosylation in antineoplastic drug action.

155 late kinase is involved in antimicrobial and antineoplastic drug activation.

156 nged exposure of lung-resident tumors to the antineoplastic drug and reduced local toxicity.

157 tudy, we monitored the cellular responses to antineoplastic drug at a single cell basis with Raman sp

158 tential to augment preclinical evaluation of antineoplastic drug candidates for these malignancies.

159 Here we show that the antineoplastic drug carmofur, which is used in the clini

160 effectively treat gliomas by reaching a high antineoplastic drug concentration at the target site wit

161 ationale can be proposed for intraperitoneal antineoplastic drug delivery in non-ovarian malignant di

162 has been proposed as a potential target for antineoplastic drug design.

163 is has recently become a suitable target for antineoplastic drug development.

164 rmacogenomics in which ethnic differences in antineoplastic drug disposition are anticipated.

165 I) chloride hexahydrate (CoCl2.6H2O) and the antineoplastic drug doxorubicin.

166 Ethonafide is an anthracene-based antineoplastic drug similar to MIT.

167 The antineoplastic drug sorafenib (BAY 43-9006) is a multiki

168 n over the past decade, yet most preclinical antineoplastic drug testing is still reliant on conventi

169 he nucleoside analogue floxuridine, a potent antineoplastic drug used in the clinic to treat advanced

170 Paclitaxel is a microtubule-targeting antineoplastic drug widely used in human cancers.

171 The efficacy of ifosfamide (IFO), an antineoplastic drug, is severely limited by a high incid

172 The therapeutic efficacy of the widely used antineoplastic drugs doxorubicin, cisplatin, vincristine

173 Prices of topical antineoplastic drugs had the greatest mean absolute and

174 Moreover, the local toxicity induced by antineoplastic drugs is considered a major obstacle for

175 side effect associated with cancer-treating antineoplastic drugs is the development of neuropathic p

176 ABCG2 expression was sensitive to antineoplastic drugs since exposure to 5 muM doxorubicin

177 Microtubule-damaging agents (MDA) are potent antineoplastic drugs that are widely used in clinical tr

178 witch is a rational target for the design of antineoplastic drugs that selectively inhibit PKCepsilon

179 making the tumor cells further resistant to antineoplastic drugs.

180 ity and alter the pharmacokinetic profile of antineoplastic drugs.

181 ffects of reactive oxygen species-generating antineoplastic drugs.

182 lective, small-molecule kinase inhibitors as antineoplastic drugs.

183 ng strategies as a means of developing novel antineoplastic drugs.

184 so induced partial cross-resistance to other antineoplastic drugs.

185 n countries and has been reported to have an antineoplastic effect both in vitro and in vivo.

186 sufficient and successful strategy to induce antineoplastic effect in hematologic tumors.

187 cal data suggest that folic acid may have an antineoplastic effect in the large intestine.

188 We conclude that the antineoplastic effect of Combo NP works by first targeti

189 RhoB, a mediator of the antineoplastic effect of FTIs and a protein inducible by

190 n; however, their relative importance in the antineoplastic effect of FTIs may vary in different cell

191 ies support the antiviral, antifibrotic, and antineoplastic effect of interferon therapy.

192 To study the antineoplastic effect of vitamin D analogues in a xenogr

193 Resistant starch has been associated with an antineoplastic effect on the colon.

194 molecular weight heparins (LMWHs), exert an antineoplastic effect through multiple mechanisms, inclu

195 This strong antineoplastic effect was successfully recapitulated by

196 uggest that some alleles of ATM may exert an antineoplastic effect, perhaps by altering the activity

197 apacity of reducing GVHD plus increasing the antineoplastic effectiveness of GVM, ex vivo virotherapy

198 in plus pyridoxine mediates immune-dependent antineoplastic effects against NSCLC.

199 ible allogeneic NK cells might have superior antineoplastic effects against solid tumors compared wit

200 understanding of the action of vitamin D3 in antineoplastic effects and the role of Beclin1 in regula

201 Metformin exhibits antiproliferative and antineoplastic effects associated with inhibition of mam

202 esponse it engenders produce potent, lasting antineoplastic effects in animal tumor models.

203 HDACIs have antineoplastic effects in preclinical and clinical trial

204 tuent of licorice, has been shown to exhibit antineoplastic effects in prostate cancer cell lines by

205 Whether epigenetic drugs produce antineoplastic effects in vivo in patients with ASM and

206 Notably, these antineoplastic effects induced by either shRNAs or small

207 at least one explanation for the remarkable antineoplastic effects observed by some ES tumor patient

208 The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch

209 incorporated 5-FU plays a major role in the antineoplastic effects of FdUrd.

210 The mechanisms of generation of the antineoplastic effects of interferons (IFNs) in malignan

211 However, the mechanisms underlying the antineoplastic effects of NSAIDs are currently unclear.

212 However, the mechanisms underlying the antineoplastic effects of NSAIDs remain unclear.

213 To discriminate between antineoplastic effects of NSAIDs that are mediated by ei

214 t part of the anti-inflammatory and putative antineoplastic effects of PGJ(2) may be mediated through

215 we show that serine withdrawal increases the antineoplastic effects of phenformin (a potent biguanide

216 astic signalling pathways, and summarise the antineoplastic effects of PPAR gamma agonists in differe

217 e autophagy pathway dramatically augment the antineoplastic effects of SAHA in CML cell lines and pri

218 on, AK295 did not interfere with the primary antineoplastic effects of Taxol on microtubules and cell

219 In this study, we investigated the antineoplastic effects of the PPARgamma agonist pioglita

220 Mnk kinase pathway in the generation of the antineoplastic effects of type I IFNs in Jak2V617F-depen

221 evertheless, the mechanisms underlying these antineoplastic effects remain poorly understood.

222 umor therapy, although the mechanisms of its antineoplastic effects remain unclear.

223 e mechanism by which HDAC inhibitors mediate antineoplastic effects remains elusive.

224 No antineoplastic effects were induced by pioglitazone in g

225 I)-containing complexes have shown promising antineoplastic effects when tested in a host of malignan

226 )-independent pathways in celecoxib-mediated antineoplastic effects, the following two issues remain

227 models suggest that thiazolidinediones have antineoplastic effects, whereas in vivo studies have pro

228 entrations of this compound are required for antineoplastic effects.

229 etabolic effects, PPARgamma agonists exhibit antineoplastic effects.

230 ition of ubiquitin isopeptidase activity and antineoplastic effects.

231 replacement, anti-inflammatory effects, and antineoplastic effects.

232 fn2 and Slfn3, Slfn5 also exhibits important antineoplastic effects.

233 The antineoplastic efficacy of anthracyclines is limited by

234 cted GBM cells is a core requirement for the antineoplastic efficacy of PVSRIPO.

235 e, a beta-blocker, an antidepressant, and an antineoplastic) frequently found in surface water were s

236 t mice revealed that this protein exerts its antineoplastic function through the regulation of the in

237 Azidothymidine was studied as an antineoplastic in the 1990s, but despite promising in vi

238 nd tumor-suppressive interleukin-10, whereas antineoplastic interleukin-12 was increased.

239 As a potential target for antineoplastic intervention, we designed IMPCH inhibitor

240 aling; inhibiting it is a valid strategy for antineoplastic intervention.

241 PBK/TOPK may therefore be a valid target for antineoplastic kinase inhibitors to sensitize tumor cell

242 We have elucidated the antineoplastic mechanism for Aurora B kinase inhibitors

243 Targeting Sox2(+) cells with the antineoplastic mithramycin abrogated tumor growth.

244 These findings suggest a novel antineoplastic molecular effect of mesalamine.

245 Auristatins, synthetic analogues of the antineoplastic natural product Dolastatin 10, are ultrap

246 As established previously, NN stimulated antineoplastic or cytostatic signaling and phenotype in

247 role in detoxifying carcinogens, activating antineoplastic prodrugs, metabolizing chemotherapeutic a

248 therapy for bipolar disorders, has selective antineoplastic properties against cancers that harbor th

249 normal stromal cells, MSCs possess intrinsic antineoplastic properties and that this stem cell popula

250 esponse modifiers that independently display antineoplastic properties can enhance TRAIL-induced apop

251 s problem is identifying agents that display antineoplastic properties concomitant with their immunos

252 genic signals in blood malignancies, BTK has antineoplastic properties in other contexts, such as the

253 polyunsaturated fatty acids (PUFAs) may have antineoplastic properties in the colon.

254 A range of antineoplastic properties is attributed to aspirin, thou

255 The molecular mechanisms underlying the antineoplastic properties of metformin, a first-line dru

256 idal anti-inflammatory drugs (NSAID) exhibit antineoplastic properties, but conventional NSAIDs do no

257 erferons (IFNs) have important antiviral and antineoplastic properties, but the precise mechanisms re

258 r normally resistant tumors sensitive to its antineoplastic properties.

259 nge of physiological activity as well as its antineoplastic properties.

260 quaternary benzophenanthridine alkaloid with antineoplastic properties.

261 The two known antineoplastic quinoxaline topoisomerase II poisons, XK4

262 and vomiting is a common side-effect of many antineoplastic regimens and can occur for several days a

263 comitant chemotherapy delivery and increased antineoplastic response in murine models of PDA.

264 k was found between CP110 and CDK2 inhibitor antineoplastic response.

265 N signaling and the generation of type I IFN antineoplastic responses.

266 This reveals a novel antineoplastic role of AID that can be triggered by inhi

267 Here, we review PPAR gamma-induced antineoplastic signalling pathways, and summarise the an

268 dered in the design of chemopreventative and antineoplastic strategies that involve inhibition of Bcl

269 e that targeting TRPC6 in HCC may be a novel antineoplastic strategy, especially combined with chemot

270 stress-signaling pathway represent potential antineoplastic targets.

271 s and has emerged as a productive target for antineoplastic therapeutic intervention.

272 a is a potential target for developing novel antineoplastic therapeutic strategies.

273 gimens, new immunosuppressive therapies, new antineoplastic therapies administered before hematopoiet

274 ical interactions between antiretroviral and antineoplastic therapies and consider how to combine ant

275 parameters, discontinuation of all previous antineoplastic therapies at least 6 weeks before interve

276 Antineoplastic therapies offer significant benefit, but

277 Two signaling pathways are activated by antineoplastic therapies that damage DNA and stall repli

278 temporary development of rationally designed antineoplastic therapies, cladribine was identified as a

279 ugs inhibiting MTOR are increasingly used in antineoplastic therapies.

280 ents in many tumour types and can complement antineoplastic therapies.

281 other compounds in clinical development for antineoplastic therapies.

282 t failure and a debilitating complication of antineoplastic therapies.

283 d bone metastases were stratified by type of antineoplastic therapy received and randomly assigned to

284 ndomized controlled trials in which standard antineoplastic therapy was used with and without bevaciz

285 ession is a life-threatening complication of antineoplastic therapy, but treatment is restricted to a

286 ion by antibodies may be a clinically viable antineoplastic therapy, particularly for melanoma.

287 fecting tumors represent a novel strategy of antineoplastic therapy.

288 history of previous hematologic disorder or antineoplastic therapy.

289 nd as a predictive marker of the response to antineoplastic therapy.

290 hat this peptide could be a novel target for antineoplastic therapy.

291 suggest that Shp2 may be a novel target for antineoplastic therapy.

292 xicities of NSAIDs have limited their use as antineoplastic therapy.

293 Tubulin is a well-established target of antineoplastic therapy; however, tubulin-targeting agent

294 and its analogs, which are now in trials as antineoplastic therapy; these agents show particular pro

295 To study the genotoxic effects of antineoplastic treatment in children, we performed a com

296 ive needs of older cancer patients receiving antineoplastic treatment.

297 Changes in antineoplastic treatments and transplant practices are d

298 Therefore, NCL is an attractive target for antineoplastic treatments.

299 plementation of (45)Ti-PET in titanium-based antineoplastics using the showcase compound [(45)Ti](sal

300 tinely been enrolled onto phase I studies of antineoplastics without clinically meaningful increase i